Therapeutic anti-CD3 monoclonal antibodies: From bench to bedside

Immunotherapy

Volumn 8, Issue 8, 2016, Pages 889-906

  Kuhn, Chantal ^a   Weiner, Howard L ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Autoimmune diseases; foralumab; immune tolerance; immunotherapy; monoclonal CD3 antibodies; otelixizumab; teplizumab; Tregs; Type 1diabetes; Visilizumab

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FORALUMAB; HYDROCORTISONE; INDOMETACIN; INSULIN; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY 145 2C11; MONOCLONAL ANTIBODY CD3; OKT 3; OTELIXIZUMAB; PENTOXIFYLLINE; PLACEBO; RAPAMYCIN; TEPLIZUMAB; UNCLASSIFIED DRUG; VISILIZUMAB; CD3 ANTIGEN; MONOCLONAL ANTIBODY;

ACUTE GRAFT REJECTION; AUTOIMMUNE DISEASE; CROHN DISEASE; CYTOKINE RELEASE SYNDROME; DIABETES MELLITUS; DOSE RESPONSE; DRUG COMPETITION; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; HEART DISEASE; HUMAN; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; INFECTION; INFLAMMATORY BOWEL DISEASE; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY GRAFT REJECTION; LOW DRUG DOSE; LYMPHOCYTOPENIA; MULTIPLE SCLEROSIS; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT; VASCULAR DISEASE; ANIMAL; AUTOIMMUNE DISEASES; CLINICAL TRIAL (TOPIC); DISEASE MODEL; IMMUNOLOGY; PROCEDURES;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD3; AUTOIMMUNE DISEASES; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; HUMANS; IMMUNE TOLERANCE; IMMUNOTHERAPY; T-LYMPHOCYTES, REGULATORY;

EID: 84979035031     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt-2016-0049     Document Type: Review

References (138)

1. Kung P, Goldstein G, Reinherz EL, Schlossman SF. Monoclonal antibodies defining distinctive human T cell surface antigens. Science 206(4416), 347-349 (1979).
2. Hooks MA, Wade CS, Millikan WJ. Muromonab CD-3: a review of its pharmacology, pharmacokinetics, and clinical use in transplantation. Pharmacotherapy 11(1), 26-37 (1991).
3. Weinshenker BG, Bass B, Karlik S, Ebers GC, Rice GP. An open trial of OKT3 in patients with multiple sclerosis. Neurology 41(7), 1047-1052 (1991).
4. Chatenoud L, Baudrihaye MF, Chkoff N, Kreis H, Goldstein G, Bach J-F. Restriction of the human in vivo immune response against the mouse monoclonal antibody OKT3. J. Immunol. 137(3), 830-838 (1986).
5. Lobo PI, Patel HC. Murine monoclonal IgG antibodies: differences in their IgG isotypes can affect the antibody effector activity when using human cells. Immunol. Cell Biol. 75(3), 267-274 (1997).
6. Sgro C. Side-effects of a monoclonal antibody, muromonab CD3/orthoclone OKT3: bibliographic review. Toxicology 105(1), 23-29 (1995).
7. Leo O, Foo M, Sachs DH, Samelson LE, Bluestone JA. Identification of a monoclonal antibody specific for a murine T3 polypeptide. Proc. Natl Acad. Sci. USA 84(5), 1374-1378 (1987).
8. Chatenoud L, Thervet E, Primo J, Bach J-F. Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc. Natl Acad. Sci. USA 91(1), 123-127 (1994).
9. Chatenoud L, Waldmann H. CD3 monoclonal antibodies: a first step towards operational immune tolerance in the clinic. Rev. Diabet. Stud. 9(4), 372-381 (2012).
10. Almagro JC, Fransson J. Humanization of antibodies. Front. Biosci. 13, 1619-1633 (2008).
11. Ferran C, Sheehan K, Dy M et al. Cytokine-related syndrome following injection of anti-CD3 monoclonal antibody: Further evidence for transient in vivo T cell activation. Eur. J. Immunol. 20(3), 509-515 (1990).
12. Hirsch R, Eckhaus M, Auchincloss H, Sachs DH, Bluestone JA. Effects of in vivo administration of anti-T3 monoclonal antibody on T cell function in mice. I. Immunosuppression of transplantation responses. J. Immunol. 140(11), 3766-3772 (1988).
13. Chatenoud L, Primo J, Bach J-F. CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice. J. Immunol. 158(6), 2947-2954 (1997).
14. Bolt S, Routledge E, Lloyd I et al. The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties. Eur. J. Immunol. 23(2), 403-411 (1993).
15. Alegre ML, Peterson LJ, Xu D et al. A non-activating "humanized" anti-CD3 monoclonal antibody retains immunosuppressive properties in vivo. Transplantation 57(11), 1537-1543 (1994).
16. Chatenoud L, Bluestone JA. CD3-specific antibodies: a portal to the treatment of autoimmunity. Nat. Rev. Immunol. 7(8), 622-632 (2007).
17. Yuan X, Cheng G, Malek TR. The importance of regulatory T-cell heterogeneity in maintaining self-tolerance. Immunol. Rev. 259(1), 103-114 (2014).
18. Burzyn D, Benoist C, Mathis D. Regulatory T cells in nonlymphoid tissues. Nat. Immunol. 14(10), 1007-1013 (2013).
19. Hsieh C-S, Liang Y, Tyznik AJ, Self SG, Liggitt D, Rudensky AY. Recognition of the peripheral self by naturally arising CD25+ CD4+ T cell receptors. Immunity 21(2), 267-277 (2004).
20. Jordan MS, Boesteanu A, Reed AJ et al. Thymic selection of CD4+CD25+ regulatory T cells induced by an agonist self-peptide. Nat. Immunol. 2(4), 301-306 (2001).
21. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 155(3), 1151-1164 (1995).
22. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat. Immunol. 4(4), 330-336 (2003).
23. Ziegler SF. FOXP3: of mice and men. Annu. Rev. Immunol. 24, 209-226 (2006).
24. Bilate AM, Lafaille JJ. Induced CD4+Foxp3+ regulatory T cells in immune tolerance. Annu. Rev. Immunol. 30, 733-758 (2012).
25. Pot C, Apetoh L, Kuchroo VK. Seminars in immunology. Semin. Immunol. 23(3), 202-208 (2011).
26. Weiner HL, da Cunha AP, Quintana F, Wu H. Oral tolerance. Immunol. Rev. 241(1), 241-259 (2011).
27. Tran DQ. TGF-: the sword, the wand, and the shield of FOXP3+ regulatory T cells. J. Mol. Cell Biol. 4(1), 29-37 (2012).
28. Peterson RA. Regulatory T-cells: diverse phenotypes integral to immune homeostasis and suppression. Toxicol. Pathol. 40(2), 186-204 (2012).
29. Asseman C, Mauze S, Leach MW, Coffman RL, Powrie F. An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. J. Exp. Med. 190(7), 995-1004 (1999).
30. Powrie F, Carlino J, Leach MW, Mauze S, Coffman RL. A critical role for transforming growth factor-beta but not interleukin 4 in the suppression of T helper type 1-mediated colitis by CD45RB(low) CD4+ T cells. J. Exp. Med. 183(6), 2669-2674 (1996).
31. Collison LW, Workman CJ, Kuo TT et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 450(7169), 566-569 (2007).
32. Grossman WJ, Verbsky JW, Tollefsen BL, Kemper C, Atkinson JP, Ley TJ. Differential expression of granzymes A and B in human cytotoxic lymphocyte subsets and T regulatory cells. Blood 104(9), 2840-2848 (2004).
33. Hänig J, Lutz MB. Suppression of mature dendritic cell function by regulatory T cells in vivo is abrogated by CD40 licensing. J. Immunol. 180(3), 1405-1413 (2008).
34. Liang B, Workman C, Lee J et al. Regulatory T cells inhibit dendritic cells by lymphocyte activation gene-3 engagement of MHC class II. J. Immunol. 180(9), 5916-5926 (2008).
35. Schmitt EG, Williams CB. Generation and function of induced regulatory T cells. Front. Immunol. 4, 152 (2013).
36. Brusko TM, Putnam AL, Bluestone JA. Human regulatory T cells: role in autoimmune disease and therapeutic opportunities. Immunol. Rev. 223, 371-390 (2008).
37. Tran GT, Carter N, He XY et al. Reversal of experimental allergic encephalomyelitis with non-mitogenic, non-depleting anti-CD3 mAb therapy with a preferential effect on T(h)1 cells that is augmented by IL-4. Int. Immunol. 13(9), 1109-1120 (2001).
38. Kohm AP, Williams JS, Bickford AL et al. Treatment with Nonmitogenic Anti-CD3 Monoclonal Antibody Induces CD4+ T Cell Unresponsiveness and Functional Reversal of Established Experimental Autoimmune Encephalomyelitis. J. Immunol. 174(8), 4525-4534 (2005).
39. Lúdvíksson BR, Ehrhardt RO, Strober W. TGF-beta production regulates the development of the 2,4,6-trinitrophenol-conjugated keyhole limpet hemocyanin-induced colonic inflammation in IL-2-deficient mice. J. Immunol. 159(7), 3622-3628 (1997).
40. Hughes C, Wolos JA, Giannini EH, Hirsch R. Induction of T helper cell hyporesponsiveness in an experimental model of autoimmunity by using nonmitogenic anti-CD3 monoclonal antibody. J. Immunol. 153(7), 3319-3325 (1994).
41. Blazar BR, Taylor PA, Vallera DA. In vivo or in vitro anti-CD3 epsilon chain monoclonal antibody therapy for the prevention of lethal murine graft-versus-host disease across the major histocompatibility barrier in mice. J. Immunol. 152(7), 3665-3674 (1994).
42. Blazar BR, Jenkins MK, Taylor PA et al. Anti-CD3 epsilon F(ab')2 fragments inhibit T cell expansion in vivo during graft-versus-host disease or the primary immune response to nominal antigen. J. Immunol. 159(12), 5821-5833 (1997).
43. Nicolls MR, Aversa GG, Pearce NW et al. Induction of long-term specific tolerance to allografts in rats by therapy with an anti-CD3-like monoclonal antibody. Transplantation 55(3), 459-468 (1993).
44. Plain KM, Chen J, Merten S, He XY, Hall BM. Induction of specific tolerance to allografts in rats by therapy with non-mitogenic, non-depleting anti-CD3 monoclonal antibody: association with TH2 cytokines not anergy. Transplantation 67(4), 605-613 (1999).
45. You S, Zuber J, Kuhn C et al. Induction of Allograft Tolerance by Monoclonal CD3 Antibodies: A Matter of Timing. Am. J. Transplant. 12(11), 2909-2919 (2012).
46. Goto R, You S, Zaitsu M, Chatenoud L, Wood KJ. Delayed anti-CD3 therapy results in depletion of alloreactive T cells and the dominance of Foxp3+ CD4+ graft infiltrating cells. Am. J. Transplant. 13(7), 1655-1664 (2013).
47. Kita T, Yamashita T, Sasaki N et al. Regression of atherosclerosis with anti-CD3 antibody via augmenting a regulatory T-cell response in mice. Cardiovasc. Res. 102(1), 107-117 (2014).
48. Chatenoud L. CD3-specific antibodies restore self-tolerance: mechanisms and clinical applications. Curr. Opin. Immunol. 17(6), 632-637 (2005).
49. Tunnacliffe A, Olsson C, la Hera de A. The majority of human CD3 epitopes are conferred by the epsilon chain. Int. Immunol. 1(5), 546-550 (1989).
50. Salmerón A, Sánchez-Madrid F, Ursa MA, Fresno M, Alarcón B. A conformational epitope expressed upon association of CD3-epsilon with either CD3-delta or CD3-gamma is the main target for recognition by anti-CD3 monoclonal antibodies. J. Immunol. 147(9), 3047-3052 (1991).
51. You S, Candon S, Kuhn C, Bach J-F, Chatenoud L. word. Adv. Immunol. 100, 13-37 (2008).
52. Chatenoud L, Baudrihaye MF, Kreis H, Goldstein G, Schindler J, Bach J-F. Human in vivo antigenic modulation induced by the anti-T cell OKT3 monoclonal antibody. Eur. J. Immunol. 12(11), 979-982 (1982).
53. Smith JA, Tso JY, Clark MR, Cole MS, Bluestone JA. Nonmitogenic anti-CD3 monoclonal antibodies deliver a partial T cell receptor signal and induce clonal anergy. J. Exp. Med. 185(8), 1413-1422 (1997).
54. Penaranda C, Tang Q, Bluestone JA. Anti-CD3 therapy promotes tolerance by selectively depleting pathogenic cells while preserving regulatory T cells. J. Immunol. 187(4), 2015-2022 (2011).
55. Valle A, Barbagiovanni G, Jofra T et al. Heterogeneous CD3 expression levels in differing T cell subsets correlate with the in vivo anti-CD3-mediated T cell modulation. J. Immunol. 194(5), 2117-2127 (2015).
56. Herold KC, Burton JB, Francois F, Poumian-Ruiz E, Glandt M, Bluestone JA. Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1(Ala-Ala). J. Clin. Invest. 111(3), 409-418 (2003).
57. Kuhn C, You S, Valette F et al. Human CD3 Transgenic Mice: Preclinical Testing of Antibodies Promoting Immune Tolerance. Sci. Transl. Med. 3(68), 68ra10-68ra10 (2011).
58. Perruche S, Zhang P, Liu Y, Saas P, Bluestone JA, Chen W. CD3-specific antibody-induced immune tolerance involves transforming growth factor-beta from phagocytes digesting apoptotic T cells. Nat. Med. 14(5), 528-535 (2008).
59. Belghith M, Bluestone JA, Barriot S, Mégret J, Bach J-F, Chatenoud L. TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat. Med. 9(9), 1202-1208 (2003).
60. Travis MA, Sheppard D. TGF-α activation and function in immunity. Annu. Rev. Immunol. 32, 51-82 (2014).
61. Chen W, Jin W, Hardegen N et al. Conversion of peripheral CD4+CD25-naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J. Exp. Med. 198(12), 1875-1886 (2003).
62. Kehrl JH, Wakefield LM, Roberts AB et al. Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth. J. Exp. Med. 163(5), 1037-1050 (1986).
63. Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu. Rev. Immunol. 21, 685-711 (2003).
64. You S, Leforban B, Garcia C, Bach J-F, Bluestone JA, Chatenoud L. Adaptive TGF-beta-dependent regulatory T cells control autoimmune diabetes and are a privileged target of anti-CD3 antibody treatment. Proc. Natl Acad. Sci. USA 104(15), 6335-6340 (2007).
65. Esplugues E, Huber S, Gagliani N et al. Control of T. Nature 475(7357), 514-518 (2012).
66. Waldron-Lynch F, Henegariu O, Deng S et al. Teplizumab induces human gut-tropic regulatory cells in humanized mice and patients. Sci. Transl. Med. 4(118), 118ra12 (2012).
67. Vossenkämper A, Hundsrucker C, Page K et al. A CD3-specific antibody reduces cytokine production and alters phosphoprotein profiles in intestinal tissues from patients with inflammatory bowel disease. Gastroenterology 147(1), 172-183 (2014).
68. Shouval DS, Ouahed J, Biswas A et al. Interleukin 10 receptor signaling: master regulator of intestinal mucosal homeostasis in mice and humans. Adv. Immunol. 122, 177-210 (2014).
69. Yu QT, Saruta M, Papadakis KA. Visilizumab induces apoptosis of mucosal T lymphocytes in ulcerative colitis through activation of caspase 3 and 8 dependent pathways. Clin. Immunol. 127(3), 322-329 (2008).
70. Ablamunits V, Bisikirska B, Herold KC. Acquisition of regulatory function by human CD8(+) T cells treated with anti-CD3 antibody requires TNF. Eur. J. Immunol. 40(10), 2891-2901 (2010).
71. Ochi H, Abraham M, Ishikawa H et al. Oral CD3-specific antibody suppresses autoimmune encephalomyelitis by inducing CD4+CD25?LAP+ T cells. Nat. Med. 12(6), 627-635 (2006).
72. Apostolou I, Boehmer von H. In vivo instruction of suppressor commitment in naive T cells. J. Exp. Med. 199(10), 1401-1408 (2004).
73. Kretschmer K, Apostolou I, Hawiger D, Khazaie K, Nussenzweig MC, Boehmer von H. Inducing and expanding regulatory T cell populations by foreign antigen. Nat. Immunol. 6(12), 1219-1227 (2005).
74. Zhang X. Recovery from experimental allergic encephalomyelitis is TGF-dependent and associated with increases in CD4+LAP+ and CD4+CD25+ T cells. Int. Immunol. 18(4), 495-503 (2006).
75. Ishikawa H, Ochi H, Chen ML, Frenkel D, Maron R, Weiner HL. Inhibition of Autoimmune Diabetes by Oral Administration of Anti-CD3 Monoclonal Antibody. Diabetes 56(8), 2103-2109 (2007).
76. Wu HY, Quintana FJ, Weiner HL. Nasal Anti-CD3 Antibody Ameliorates Lupus by Inducing an IL-10-Secreting CD4+CD25-LAP+ Regulatory T Cell and Is Associated with Down-Regulation of IL-17+CD4+ICOS+CXCR5+ Follicular Helper T Cells. J. Immunol. 181(9), 6038-6050 (2008).
77. Wu HY, Maron R, Tukpah AM, Weiner HL. Mucosal anti-CD3 monoclonal antibody attenuates collagen-induced arthritis that is associated with induction of LAP+ regulatory T cells and is enhanced by administration of an emulsome-based Th2-skewing adjuvant. J. Immunol. 185(6), 3401-3407 (2010).
78. Forster K, Goethel A, Chan CWT, Zanello G, Streutker C, Croitoru K. An oral CD3-Specific antibody suppresses T-cell-induced colitis and alters cytokine responses to T-cell activation in mice. Gastroenterology 143(5), 1298-1307 (2012).
79. Ilan Y, Maron R, Tukpah A-M et al. Induction of regulatory T cells decreases adipose inflammation and alleviates insulin resistance in ob/ob mice. Proc. Natl Acad. Sci. USA 107(21), 9765-9770 (2010).
80. Sasaki N, Yamashita T, Takeda M et al. Oral anti-CD3 antibody treatment induces regulatory T cells and inhibits the development of atherosclerosis in mice. Circulation 120(20), 1996-2005 (2009).
81. Miyamoto K, Kingsley CI, Zhang X et al. The ICOS molecule plays a crucial role in the development of mucosal tolerance. J. Immunol. 175(11), 7341-7347 (2005).
82. Peron JPS, de Oliveira APL, Rizzo LV. Autoimmunity Reviews. Autoimmun. Rev. 9(1), 1-4 (2009).
83. Slavin AJ, Maron R, Weiner HL. Mucosal administration of IL-10 enhances oral tolerance in autoimmune encephalomyelitis and diabetes. Int. Immunol. 13(6), 825-833 (2001).
84. Ochi H, Abraham M, Ishikawa H et al. New immunosuppressive approaches: Oral administration of CD3-specific antibody to treat autoimmunity. J. Neurol. Sci. 274(1-2), 9-12 (2008).
85. da Cunha AP, Weiner HL. Induction of immunological tolerance by oral anti-CD3. Clin. Dev. Immunol. 2012, 425021 (2012).
86. Andersson J, Tran DQ, Pesu M et al. CD4+FoxP3+ regulatory T cells confer infectious tolerance in a TGF-dependent manner. J. Exp. Med. 205(9), 1975-1981 (2008).
87. Chen M-L, Yan B-S, Bando Y, Kuchroo VK, Weiner HL. Latency-associated peptide identifies a novel CD4+CD25+ regulatory T cell subset with TGFbeta-mediated function and enhanced suppression of experimental autoimmune encephalomyelitis. J. Immunol. 180(11), 7327-7337 (2008).
88. Oliveira VG, Caridade M, Paiva RS, Demengeot J, Graca L. Sub-optimal CD4+ T-cell activation triggers autonomous TGF-?-dependent conversion to Foxp3+ regulatory T cells. Eur. J. Immunol. 41(5), 1249-1255 (2011).
89. Wu H, Center E, Tsokos G, Weiner H. Suppression of murine SLE by oral anti-CD3: inducible CD4+CD25-LAP+ regulatory T cells control the expansion of IL-17+ follicular helper T cells. Lupus 18(7), 586-596 (2009).
90. Wu HY, Quintana FJ, da Cunha AP et al. In vivo induction of Tr1 cells via mucosal dendritic cells and AHR signaling. PLoS ONE 6(8), e23618 (2011).
91. Cole MS, Stellrecht KE, Shi JD et al. HuM291, a humanized anti-CD3 antibody, is immunosuppressive to T cells while exhibiting reduced mitogenicity in vitro. Transplantation 68(4), 563-571 (1999).
92. Dean Y, Dépis F, Kosco-Vilbois M. Combination therapies in the context of anti-CD3 antibodies for the treatment of autoimmune diseases. Swiss Med. Wkly 142, w13711 (2012).
93. Friend PJ, Hale G, Chatenoud L et al. Phase I study of an engineered aglycosylated humanized CD3 antibody in renal transplant rejection. Transplantation 68(11), 1632-1637 (1999).
94. Alegre ML, Tso JY, Sattar HA et al. An anti-murine CD3 monoclonal antibody with a low affinity for Fc gamma receptors suppresses transplantation responses while minimizing acute toxicity and immunogenicity. J. Immunol. 155(3), 1544-1555 (1995).
95. Herold KC, Hagopian W, Auger JA et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N. Engl. J. Med. 346(22), 1692-1698 (2002).
96. Herold KC, Gitelman SE, Masharani U et al. A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 54(6), 1763-1769 (2005).
97. Keymeulen B, Vandemeulebroucke E, Ziegler AG et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N. Engl. J. Med. 352(25), 2598-2608 (2005).
98. Keymeulen B, Walter M, Mathieu C et al. Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. Diabetologia 53(4), 614-623 (2010).
99. Sherry N, Hagopian W, Ludvigsson J et al. Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial. Lancet 378(9790), 487-497 (2011).
100. Aronson R, Gottlieb PA, Christiansen JS et al. Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: results of the randomized phase III study in recent-onset human type 1 diabetes. Diabetes Care 37(10), 2746-2754 (2014).
101. Ambery P, Donner TW, Biswas N, Donaldson J, Parkin J, Dayan CM. Efficacy and safety of low-dose otelixizumab anti-CD3 monoclonal antibody in preserving C-peptide secretion in adolescent type 1 diabetes: DEFEND-2, a randomized, placebo-controlled, double-blind, multi-centre study. Diabet. Med. 31(4), 399-402 (2014).
102. Hagopian W, Ferry RJ, Sherry N et al. Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomized, placebo-controlled Protégé trial. Diabetes 62(11), 3901-3908 (2013).
103. Herold KC, Gitelman SE, Ehlers MR et al. Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders. Diabetes 62(11), 3766-3774 (2013).
104. Plevy S, Salzberg B, Van Assche G et al. A Phase I Study of Visilizumab, a Humanized Anti-CD3 Monoclonal Antibody, in Severe Steroid-Refractory Ulcerative Colitis. Gastroenterology 133(5), 1414-1422 (2007).
105. Sandborn WJ, Colombel JF, Frankel M et al. Anti-CD3 antibody visilizumab is not effective in patients with intravenous corticosteroid-refractory ulcerative colitis. Gut 59(11), 1485-1492 (2010).
106. van der Woude CJ, Stokkers P, van Bodegraven AA et al. Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of NI-0401 (a fully human anti-CD3 monoclonal antibody) in patients with moderate to severe active Crohn's disease. Inflamm. Bowel Dis. 16(10), 1708-1716 (2010).
107. Ilan Y, Zigmond E, Lalazar G et al. Oral administration of OKT3 monoclonal antibody to human subjects induces a dose-dependent immunologic effect in T cells and dendritic cells. J. Clin. Immunol. 30(1), 167-177 (2009).
108. Halota W, Ferenci P, Kozielewicz D et al. Oral anti-CD3 immunotherapy for HCV-nonresponders is safe, promotes regulatory T cells and decreases viral load and liver enzyme levels: results of a phase-2a placebo-controlled trial. J. Viral Hepat. 22(8), 651-657 (2015).
109. Lalazar G, Mizrahi M, Turgeman I et al. Oral administration of OKT3 MAb to patients with NASH, promotes regulatory T-cell induction, and alleviates insulin resistance: results of a phase IIa blinded placebo-controlled trial. J. Clin. Immunol. 35(4), 399-407 (2015).
110. Woodle ES, Xu D, Zivin RA et al. Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3gamma1(Ala-Ala) in the treatment of acute renal allograft rejection. Transplantation 68(5), 608-616 (1999).
111. Keymeulen B, Candon S, Fafi-Kremer S et al. Transient Epstein-Barr virus reactivation in CD3 monoclonal antibody-treated patients. Blood 115(6), 1145-1155 (2010).
112. Chatenoud L, Legendre C, Ferran C, Bach J-F, Kreis H. Corticosteroid inhibition of the OKT3-induced cytokine-related syndrome-dosage and kinetics prerequisites. Transplantation 51(2), 334-338 (1991).
113. Shield CF, Kahana L, Pirsch J et al. Use of indomethacin to minimize the adverse reactions associated with orthoclone OKT3 treatment of kidney allograft rejection. Transplantation 54(1), 164-166 (1992).
114. Alegre ML, Gastaldello K, Abramowicz D et al. Evidence that pentoxifylline reduces anti-CD3 monoclonal antibody-induced cytokine release syndrome. Transplantation 52(4), 674-679 (1991).
115. Ferran C, Dy M, Merite S et al. Reduction of morbidity and cytokine release in anti-CD3 MoAb-treated mice by corticosteroids. Transplantation 50(4), 642-648 (1990).
116. Alegre ML, Vandenabeele P, Depierreux M et al. Cytokine release syndrome induced by the 145-2C11 anti-CD3 monoclonal antibody in mice: prevention by high doses of methylprednisolone. J. Immunol. 146(4), 1184-1191 (1991).
117. Ferran C, Dy M, Sheehan K et al. Cascade modulation by anti-tumor necrosis factor monoclonal antibody of interferon-gamma, interleukin 3 and interleukin 6 release after triggering of the CD3/T cell receptor activation pathway. Eur. J. Immunol. 21(10), 2349-2353 (1991).
118. Charpentier B, Hiesse C, Lantz O et al. Evidence that antihuman tumor necrosis factor monoclonal antibody prevents OKT3-induced acute syndrome. Transplantation 54(6), 997-1002 (1992).
119. Valle A, Jofra T, Stabilini A, Atkinson M, Roncarolo M-G, Battaglia M. Rapamycin prevents and breaks the anti-CD3-induced tolerance in NOD mice. Diabetes 58(4), 875-881 (2009).
120. Belmar NA, Lombardo JR, Chao DT et al. Dissociation of efficacy and cytokine release mediated by an Fc-modified anti-CD3 mAb in a chronic experimental autoimmune encephalomyelitis model. J. Neuroimmunol. 212(1-2), 65-73 (2009).
121. Montero N, Pascual J. Immunosuppression and post-transplant hyperglycemia. Curr. Diabetes Rev. 11(3), 144-154 (2015).
122. Zhang D, Tu E, Kasagi S, Zanvit P, Chen Q, Chen W. Manipulating regulatory T cells: a promising strategy to treat autoimmunity. Immunotherapy 7(11), 1201-1211 (2015).
123. Mamchak AA, Manenkova Y, Leconet W et al. Preexisting autoantibodies predict efficacy of oral insulin to cure autoimmune diabetes in combination with anti-CD3. Diabetes 61(6), 1490-1499 (2012).
124. Takiishi T, Korf H, Van Belle TL et al. Reversal of autoimmune diabetes by restoration of antigen-specific tolerance using genetically modified Lactococcus lactis in mice. J. Clin. Invest. 122(5), 1717-1725 (2012).
125. Bresson D, Fousteri G, Manenkova Y, Croft M, Herrath von M. Journal of autoimmunity. J. Autoimmun. 37(4), 342-351 (2011).
126. Sherry NA, Chen W, Kushner JA et al. Exendin-4 improves reversal of diabetes in NOD mice treated with anti-CD3 monoclonal antibody by enhancing recovery of beta-cells. Endocrinology 148(11), 5136-5144 (2007).
127. Hering BJ, Kandaswamy R, Harmon JV et al. Transplantation of cultured islets from two-layer preserved pancreases in type 1 diabetes with anti-CD3 antibody. Am. J. Transplant. 4(3), 390-401 (2004).
128. Bellin MD, Barton FB, Heitman A et al. Potent induction immunotherapy promotes long-term insulin independence after islet transplantation in type 1 diabetes. Am. J. Transplant. 12(6), 1576-1583 (2012).
129. Begum S, Chen W, Herold KC, Papaioannou VE. Remission of type 1 diabetes after anti-CD3 antibody treatment and transplantation of embryonic pancreatic precursors. Endocrinology 150(10), 4512-4520 (2009).
130. You S, Piali L, Kuhn C et al. Therapeutic use of a selective S1P1 receptor modulator ponesimod in autoimmune diabetes. PLoS ONE 8(10), e77296 (2013).
131. Nepom GT, Ehlers M, Mandrup-Poulsen T. Anti-cytokine therapies in T1D: concepts and strategies. Clin. Immunol. 149(PA), 279-285 (2013).
132. Ablamunits V, Henegariu O, Hansen JB et al. Synergistic reversal of type 1 diabetes in NOD mice with anti-CD3 and interleukin-1 blockade: evidence of improved immune regulation. Diabetes 61(1), 145-154 (2012).
133. Malfait AM, Williams RO, Malik AS, Maini RN, Feldmann M. Chronic relapsing homologous collagen-induced arthritis in DBA/1 mice as a model for testing disease-modifying and remission-inducing therapies. Arthritis Rheum. 44(5), 1215-1224 (2001).
134. Dépis F, Hatterer E, Lamacchia C et al. Long-term amelioration of established collagen-induced arthritis achieved with short-term therapy combining anti-CD3 and anti-tumor necrosis factor treatments. Arthritis Rheum. 64(10), 3189-3198 (2012).
135. Baan CC, Gaston RS. Report of a joint ESOT and AST meeting: highlights in biologic agents and transplantation. Am. J. Transplant. 11(4), 681-686 (2011).
136. Presta LG. Molecular engineering and design of therapeutic antibodies. Curr. Opin. Immunol. 20(4), 460-470 (2008).
137. Chan AC, Carter PJ. Therapeutic antibodies for autoimmunity and inflammation. Nat. Rev. Immunol. 10(5), 301-316 (2010).
138. Reichert JM. Metrics for antibody therapeutics development. MAbs 2(6), 695-700 (2010).